Summary by Futu AI
60 Degrees Pharmaceuticals, Inc., listed on The Nasdaq Capital Market under the symbol 'SXTP', has announced an increase in the maximum aggregate gross sales price of its common stock to $2,190,416 through an At the Market Issuance Sales Agreement with WallachBeth Capital LLC. This increase, detailed in a prospectus supplement filed on July 26, 2024, amends previous registrations to allow for additional sales under the agreement. As of the filing date, 60 Degrees Pharmaceuticals has sold 7,525,879 shares for an aggregate gross sales price of $1,890,500.81. The company's outstanding common stock held by non-affiliates is valued at approximately $6,571,249, based on a share price of $0.351 as of June 7, 2024. The company adheres to the SEC's General Instruction I.B.6 of Form S-3, limiting sales to no more than one-third of their public float in a 12-month period, provided the public float remains below $75 million. Investors are advised to consider the risk factors outlined in the accompanying prospectus supplement and base prospectus, as well as other SEC filings.